Program
axatilimab
Also written as “Axatilimab”, “INCA034176” and “SNDX-6352”.
Its studies are mostly in Bronchiolitis Obliterans Syndrome · Idiopathic Pulmonary Fibrosis · Neoplasm Metastasis · Coronavirus Infections, led by 2 companies.
Drug pageAxatilimab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyteits history only | 76 open or running | phase 3since Feb 9, 2024 | Feb 9, 2024 | Jan 6, 2027phase 2 · NCT06843408 |
| Syndax Pharmaceuticals | 51 open or running | phase 2since Jul 10, 2018 | Jun 30, 2017 | none ahead |
Also a collaborator on its studies: DevPro Biopharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Syndax Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 30, 2017First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03238027 · 45 enrolled · United States
- Jul 10, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeNCT03604692 · 41 enrolled · United States
- Jun 9, 2019Named axatilimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, INCA034176, SNDX-6352
- May 29, 2020Phase 2 study in Coronavirus InfectionsNCT04415073 · 1 enrolled · United States
- Jan 5, 2021Phase 2 study in Bronchiolitis Obliterans SyndromeNCT04710576 · 296 planned · United States, Australia, Belgium and more
- Nov 9, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT06132256 · 145 enrolled · Australia, Belgium, Canada and more
TargetBeta
“A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R; CSF1R; macrophage-CSFR; M-CSFR; CD115; c-fms), ”NCIt, by rule
“Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule
Other programs on CSF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| pimicotinibrule | Abbisko Cayman | phase 3 | 14 |
| vimseltinibrule | Ono Pharmaceutical | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| adrixetinibrule | qurient-co-ltd | phase 2 | 3 |
Studies
All 5 Syndax Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06132256Idiopathic Pulmonary Fibrosis · Australia, Belgium, Canada and more | 2 | Completed | Aug 27, 2026 | 145 |
| NCT04710576Bronchiolitis Obliterans Syndrome · United States, Australia, Belgium and more | 2 | Recruiting | Apr 7, 2023 | 296 |
| NCT04415073Coronavirus Infections · United States | 2 | Terminated | Jul 13, 2020 | 1 |
| NCT03604692Bronchiolitis Obliterans Syndrome · United States | 2 | Completed | Aug 12, 2022 | 41 |
| NCT03238027Neoplasm Metastasis · United States | 1 | Completed | Nov 20, 2020 | 45 |
How it is read
Names in the registry
- “Axatilimab”, 5 entries
- “INCA034176”, 5 entries
- “axatilimab”, 1 entry
- “SNDX-6352”, 1 entry
Conditions, from the studies’ own filings
- Bronchiolitis Obliterans Syndrome, 8 studies
- Idiopathic Pulmonary Fibrosis, 1 study
- Neoplasm Metastasis, 1 study
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.